Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Northwest Biotherapeutics (NWBO) Shares Repurchased (2017 - 2018)

Northwest Biotherapeutics' Shares Repurchased history spans 2 years, with the latest figure at $855000.0 for Q4 2018.

Quarterly results put Shares Repurchased at $855000.0 for Q4 2018, up 21.28% from a year ago — trailing twelve months through Sep 2019 was $855000.0 (down 72.93% YoY), and the annual figure for FY2018 was $3.3 million, up 74.84%.
Shares Repurchased for Q4 2018 was $855000.0 at Northwest Biotherapeutics, up from $708000.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $1.1 million in Q1 2018 to a low of $2000.0 in Q1 2017.